76 results
Page 4 of 4
6-K
EX-99.1
bn26isdngq c7gh
23 Oct 18
MorphoSys’s Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference
6:02am
6-K
EX-99.1
n6rt1v
22 Oct 18
Current report (foreign)
6:09am
6-K
EX-99.1
p5nfdc4shbq5
9 Aug 18
MorphoSys andI-Mab Biopharma Announce China IND Submission of TJ202/MOR202
8:10am
6-K
EX-99.1
wua2 muvwxa
2 Aug 18
MorphoSys AG Reports Second Quarter 2018 Financial Results
6:43am
6-K
EX-99.1
dih897s9
24 Jul 18
MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial
4:06pm
6-K
EX-99.2
co35cp3k i0c9tg6
19 Jul 18
Current report (foreign)
8:52am
6-K
EX-99.1
dgu4lm2
19 Jul 18
Current report (foreign)
8:52am
6-K
EX-99.1
u4hgolzij9
10 Jul 18
MorphoSys Announces its Licensee Janssen has Initiated a
4:06pm
6-K
EX-99.1
mu5usqd
15 Jun 18
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018
12:00am
6-K
EX-99.1
82t4m9 y68w32f62
15 Jun 18
MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference
12:00am
6-K
EX-99.1
6atwr
17 May 18
Annual General Meeting of MorphoSys AG Elects New Supervisory
4:07pm
6-K
EX-99.1
s1lfw4t787srgkg7q2
17 May 18
MorphoSys Announces Presentation of Clinical Data on Proprietary
4:05pm
6-K
EX-99.1
bgrz2h7
2 May 18
First Quarter Interim Statement
4:08pm
6-K
EX-99.1
dz9o5
2 May 18
MorphoSys AG Reports First Quarter 2018 Results
4:07pm
6-K
EX-99.1
o389j1b
1 May 18
MorphoSys and Galapagos Announce Initiation of the IGUANA
4:06pm
6-K
EX-99.1
5eyg561fwr
26 Apr 18
MorphoSys Announces Approval of Tremfya® (Guselkumab) in South Korea
4:06pm